Discordance Between Cobas BRAF V600 Testing and VE1 Immunohistochemistry in a Melanoma Patient With Bone Marrow Metastases.
Publication/Presentation Date
9-1-2016
Abstract
False negative result remains an ongoing problem in direct gene sequencing of cancers. It is important to use the appropriate mutation detection method most appropriate to each circumstance and the available tissue. Here, we report a patient with melanoma of unknown primary with metastases to spleen and bone marrow, who was tested negative for Cobas BRAF V600E mutation, whose cancer progressed on antiprogrammed death 1 (PD1) receptor monoclonal antibody therapy. Subsequent VE1 immunohistochemistry was positive for BRAF V600E mutation, and the tumor responded dramatically to v-Raf murine sarcoma viral oncogene homolog B (BRAF)/Mitogen-activated protein kinase inhibitor combination therapy. This demonstrates how alternative BRAF testing methodology could produce results that can influence treatment choice and the outcome.
Volume
38
Issue
9
First Page
687
Last Page
689
ISSN
1533-0311
Published In/Presented At
Rapisuwon, S., Busam, K. J., Parks, K., Chapman, P. B., Lee, E., & Atkins, M. B. (2016). Discordance Between Cobas BRAF V600 Testing and VE1 Immunohistochemistry in a Melanoma Patient With Bone Marrow Metastases. The American Journal of dermatopathology, 38(9), 687–689. https://doi.org/10.1097/DAD.0000000000000660
Disciplines
Medicine and Health Sciences
PubMedID
27541170
Department(s)
Department of Pathology and Laboratory Medicine
Document Type
Article